Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

The neutrophil-lymphocyte ratio in early rheumatoid arthritis and its ability to predict subsequent failure of triple therapy.

Boulos D, Proudman SM, Metcalf RG, McWilliams L, Hall C, Wicks IP.

Semin Arthritis Rheum. 2019 May 31. pii: S0049-0172(19)30109-X. doi: 10.1016/j.semarthrit.2019.05.008. [Epub ahead of print]

PMID:
31248587
2.

Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis.

Ferdowsi N, Huq M, Stevens W, Hudson M, Wang M, Tay T, Burchell JL, Mancuso S, Rabusa C, Sundararajan V, Prior D, Proudman SM, Baron M, Nikpour M; Scleroderma Clinical Trials Consortium Damage Index Working Group, The Australian Scleroderma Interest Group, Canadian Scleroderma Research Group; Scleroderma Clinical Trials Consortium Damage Index Working Group, TheAustralian Scleroderma Interest Group, Canadian Scleroderma Research Group.

Ann Rheum Dis. 2019 Jun;78(6):807-816. doi: 10.1136/annrheumdis-2018-214764. Epub 2019 Mar 30. Erratum in: Ann Rheum Dis. 2019 Aug;78(8):e88.

PMID:
30928903
3.

The role of inflammatory markers in assessment of disease activity in systemic sclerosis.

Ross L, Stevens W, Rabusa C, Wilson M, Ferdowsi N, Walker J, Sahhar J, Ngian GS, Zochling J, Roddy J, Tymms K, Major G, Strickland G, Proudman SM, Nikpour M.

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):126-134. Epub 2018 Sep 29.

PMID:
30277869
4.

Determinants of health-related quality of life in a multinational systemic sclerosis inception cohort.

Morrisroe K, Hudson M, Baron M, de Vries-Bouwstra J, Carreira PE, Wuttge DM, Wang M, Frech TM, Stevens W, Proudman SM, Nikpour M; International Systemic Sclerosis Inception Cohort (INSYNC) collaboration.

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):53-60. Epub 2018 Aug 31.

5.

Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus.

Cole S, Walsh A, Yin X, Wechalekar MD, Smith MD, Proudman SM, Veale DJ, Fearon U, Pitzalis C, Humby F, Bombardieri M, Axel A, Adams H 3rd, Chiu C, Sharp M, Alvarez J, Anderson I, Madakamutil L, Nagpal S, Guo Y.

Arthritis Res Ther. 2018 May 2;20(1):85. doi: 10.1186/s13075-018-1578-z.

6.

Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression.

Guo Y, Walsh AM, Canavan M, Wechalekar MD, Cole S, Yin X, Scott B, Loza M, Orr C, McGarry T, Bombardieri M, Humby F, Proudman SM, Pitzalis C, Smith MD, Friedman JR, Anderson I, Madakamutil L, Veale DJ, Fearon U, Nagpal S.

PLoS One. 2018 Feb 28;13(2):e0192704. doi: 10.1371/journal.pone.0192704. eCollection 2018.

7.

Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study.

Herrick AL, Peytrignet S, Lunt M, Pan X, Hesselstrand R, Mouthon L, Silman AJ, Dinsdale G, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk MC, Ancuţa C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jobanputra P, Jordan AC, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov NS, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, İnanç M, McLaren JS, van Laar JM, Pathare S, Proudman SM, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP.

Ann Rheum Dis. 2018 Apr;77(4):563-570. doi: 10.1136/annrheumdis-2017-211912. Epub 2018 Jan 6.

8.

Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways.

Walsh AM, Wechalekar MD, Guo Y, Yin X, Weedon H, Proudman SM, Smith MD, Nagpal S.

PLoS One. 2017 Sep 1;12(9):e0183928. doi: 10.1371/journal.pone.0183928. eCollection 2017.

9.

Validity of the Workers Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) in patients with systemic sclerosis.

Morrisroe K, Stevens W, Huq M, Sahhar J, Ngian GS, Zochling J, Roddy J, Proudman SM, Nikpour M; Australian Scleroderma Interest Group (ASIG).

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):130-137. Epub 2017 May 8.

PMID:
28516877
10.

CD40L-Dependent Pathway Is Active at Various Stages of Rheumatoid Arthritis Disease Progression.

Guo Y, Walsh AM, Fearon U, Smith MD, Wechalekar MD, Yin X, Cole S, Orr C, McGarry T, Canavan M, Kelly S, Lin TA, Liu X, Proudman SM, Veale DJ, Pitzalis C, Nagpal S.

J Immunol. 2017 Jun 1;198(11):4490-4501. doi: 10.4049/jimmunol.1601988. Epub 2017 Apr 28.

11.

Antifibrillarin Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis.

Mejia Otero C, Assassi S, Hudson M, Mayes MD, Estrada-Y-Martin R, Pedroza C, Mills TW, Walker J, Baron M, Stevens W, Proudman SM, Nikpour M, Mehra S, Wang M, Fritzler MJ; Canadian Scleroderma Research Group; Australian Scleroderma Cohort Study; Genetics versus Environment in Scleroderma Outcome Study.

J Rheumatol. 2017 Jun;44(6):799-805. doi: 10.3899/jrheum.160574. Epub 2017 Apr 1.

12.

A Treat-to-Target Strategy Preserves Work Capacity in a Rheumatoid Arthritis Inception Cohort Treated With Combination Conventional DMARD Therapy.

Wechalekar MD, Quinn S, Lester S, Metcalf RG, Shanahan E, Walker JG, Smith MD, Hill CL, Shanahan EM, Proudman SM.

J Clin Rheumatol. 2017 Apr;23(3):131-137. doi: 10.1097/RHU.0000000000000506.

PMID:
28277345
13.

Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol.

Calderone A, Stevens W, Prior D, Nandurkar H, Gabbay E, Proudman SM, Williams T, Celermajer D, Sahhar J, Wong PK, Thakkar V, Dwyer N, Wrobel J, Chin W, Liew D, Staples M, Buchbinder R, Nikpour M.

BMJ Open. 2016 Dec 8;6(12):e011028. doi: 10.1136/bmjopen-2016-011028.

14.

Putting recommendations into practice: Australian rheumatologists' opinions on leflunomide use in rheumatoid arthritis.

Hopkins AM, Wiese MD, O'Doherty CE, Proudman SM.

Clin Rheumatol. 2017 Apr;36(4):791-798. doi: 10.1007/s10067-016-3488-2. Epub 2016 Nov 25.

PMID:
27888342
15.

Active Foot Synovitis in Patients With Rheumatoid Arthritis: Unstable Remission Status, Radiographic Progression, and Worse Functional Outcomes in Patients With Foot Synovitis in Apparent Remission.

Wechalekar MD, Lester S, Hill CL, Lee A, Rischmueller M, Smith MD, Walker JG, Proudman SM.

Arthritis Care Res (Hoboken). 2016 Nov;68(11):1616-1623. doi: 10.1002/acr.22887.

16.

The association of low complement with disease activity in systemic sclerosis: a prospective cohort study.

Esposito J, Brown Z, Stevens W, Sahhar J, Rabusa C, Zochling J, Roddy J, Walker J, Proudman SM, Nikpour M.

Arthritis Res Ther. 2016 Oct 22;18(1):246.

17.

Measures of disease status in systemic sclerosis: A systematic review.

Tay T, Ferdowsi N, Baron M, Stevens W, Hudson M, Proudman SM, Nikpour M; Damage Index Working Group of the Scleroderma Clinical Trials Consortium.

Semin Arthritis Rheum. 2017 Feb;46(4):473-487. doi: 10.1016/j.semarthrit.2016.07.010. Epub 2016 Jul 29. Review.

PMID:
27765344
18.

Determinants of unemployment amongst Australian systemic sclerosis patients: results from a multicentre cohort study.

Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman SM, Nikpour M; and the Australian Scleroderma Interest Group (ASIG).

Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):79-84. Epub 2016 Jul 8.

PMID:
27463997
19.

The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study.

Thakkar V, Stevens W, Prior D, Rabusa C, Sahhar J, Walker JG, Roddy J, Lester S, Rischmueller M, Zochling J, Nash P, Gabbay E, Youssef P, Proudman SM, Nikpour M.

Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):129-136. Epub 2016 May 23.

PMID:
27214686
20.

Intracellular CD3+ T Lymphocyte Teriflunomide Concentration Is Poorly Correlated with and Has Greater Variability Than Unbound Plasma Teriflunomide Concentration.

Hopkins AM, Moghaddami M, Foster DJ, Proudman SM, Upton RN, Wiese MD.

Drug Metab Dispos. 2017 Jan;45(1):8-16. Epub 2016 Oct 14.

PMID:
27742727
21.

Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study.

Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman SM, Nikpour M; Australian Scleroderma Interest Group (ASIG).

BMC Pulm Med. 2016 Sep 27;16(1):134.

22.

Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort.

Wabe NT, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee AT, Spargo LD, Metcalf RG, Hall C, Proudman SM, Wiese MD.

J Rheumatol. 2016 Sep;43(9):1643-9. doi: 10.3899/jrheum.151392. Epub 2016 Jul 15.

PMID:
27422892
23.

Reduced corticosteroid-binding globulin cleavage in active rheumatoid arthritis.

Nenke MA, Lewis JG, Rankin W, McWilliams L, Metcalf RG, Proudman SM, Torpy DJ.

Clin Endocrinol (Oxf). 2016 Sep;85(3):369-77. doi: 10.1111/cen.13081. Epub 2016 May 8.

PMID:
27061835
24.

Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?

Wabe N, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee A, Hall C, Spargo L, Metcalf R, Proudman SM, Wiese MD.

Int J Clin Pract. 2016 Apr;70(4):340-50. doi: 10.1111/ijcp.12785. Epub 2016 Mar 14.

PMID:
26987888
25.

Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia.

Hopkins AM, Proudman SM, Vitry AI, Sorich MJ, Cleland LG, Wiese MD.

Med J Aust. 2016 Feb 1;204(2):64-8.

PMID:
26821102
26.

A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity.

Wojciechowski J, Wiese MD, Proudman SM, Foster DJ, Upton RN.

Br J Clin Pharmacol. 2016 Jun;81(6):1046-57. doi: 10.1111/bcp.12891. Epub 2016 Apr 7.

27.

The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.

Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, Baron M, Clements PJ, Steen V, Assassi S, Schiopu E, Phillips K, Simms RW, Allanore Y, Denton CP, Distler O, Johnson SR, Matucci-Cerinic M, Pope JE, Proudman SM, Siegel J, Wong WK, Wells AU, Furst DE.

Arthritis Rheumatol. 2016 Feb;68(2):299-311. doi: 10.1002/art.39501.

28.

The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.

Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, Baron M, Clements PJ, Steen V, Assassi S, Schiopu E, Phillips K, Simms RW, Allanore Y, Denton CP, Distler O, Johnson SR, Matucci-Cerinic M, Pope JE, Proudman SM, Siegel J, Wong WK, Wells AU, Furst DE.

Arthritis Care Res (Hoboken). 2016 Feb;68(2):167-78. doi: 10.1002/acr.22804.

29.

Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis.

Wabe N, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee A, Spargo L, Metcalf R, Hall C, Proudman SM, Wiese MD.

Int J Rheum Dis. 2017 May;20(5):576-583. doi: 10.1111/1756-185X.12816. Epub 2015 Dec 22.

PMID:
26692459
30.

Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose.

Hill CL, March LM, Aitken D, Lester SE, Battersby R, Hynes K, Fedorova T, Proudman SM, James M, Cleland LG, Jones G.

Ann Rheum Dis. 2016 Jan;75(1):23-9. doi: 10.1136/annrheumdis-2014-207169. Epub 2015 Sep 9.

PMID:
26353789
31.

Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis.

Quinlivan A, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C, Youssef P, Gabbay E, Roddy J, Walker JG, Zochling J, Sahhar J, Nash P, Lester S, Rischmueller M, Proudman SM, Nikpour M.

Intern Med J. 2015 Nov;45(11):1134-40. doi: 10.1111/imj.12890.

PMID:
26337683
32.

Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.

Hopkins AM, Wiese MD, Proudman SM, O'Doherty CE, Upton RN, Foster DJ.

Br J Clin Pharmacol. 2016 Jan;81(1):113-23. doi: 10.1111/bcp.12760. Epub 2015 Oct 28.

33.

Plasma n-3 fatty acids and clinical outcomes in recent-onset rheumatoid arthritis.

Proudman SM, Cleland LG, Metcalf RG, Sullivan TR, Spargo LD, James MJ.

Br J Nutr. 2015 Sep 28;114(6):885-90. doi: 10.1017/S0007114515002718. Epub 2015 Aug 18.

PMID:
26283657
34.

Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis.

Patterson KA, Roberts-Thomson PJ, Lester S, Tan JA, Hakendorf P, Rischmueller M, Zochling J, Sahhar J, Nash P, Roddy J, Hill C, Nikpour M, Stevens W, Proudman SM, Walker JG.

Arthritis Rheumatol. 2015 Dec;67(12):3234-44. doi: 10.1002/art.39316.

35.

Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease.

Moore OA, Proudman SM, Goh N, Corte TJ, Rouse H, Hennessy O, Morrisroe K, Thakkar V, Sahhar J, Roddy J, Youssef P, Gabbay E, Nash P, Zochling J, Stevens W, Nikpour M.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S111-6. Epub 2015 Aug 5.

PMID:
26243401
36.

Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.

Hopkins AM, Wiese MD, Proudman SM, O'Doherty CE, Foster D, Upton RN.

CPT Pharmacometrics Syst Pharmacol. 2015 Jun;4(6):362-71. doi: 10.1002/psp4.46. Epub 2015 Jun 15.

37.

Musculoskeletal Manifestations of Systemic Sclerosis.

Morrisroe KB, Nikpour M, Proudman SM.

Rheum Dis Clin North Am. 2015 Aug;41(3):507-18. doi: 10.1016/j.rdc.2015.04.011. Epub 2015 May 26. Review.

PMID:
26210132
38.

Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide.

Hopkins AM, Vitry AI, O'Doherty CE, Proudman SM, Wiese MD.

Int J Rheum Dis. 2017 Nov;20(11):1795-1797. doi: 10.1111/1756-185X.12717. Epub 2015 Jul 14. No abstract available.

PMID:
26176865
39.

Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years.

Wabe N, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee A, Spargo L, Metcalf RG, Hall C, Proudman SM, Wiese MD.

Arthritis Res Ther. 2015 Mar 8;17:48. doi: 10.1186/s13075-015-0562-0.

40.

Is there a link between carbamylation and citrullination in periodontal disease and rheumatoid arthritis?

Bright R, Proudman SM, Rosenstein ED, Bartold PM.

Med Hypotheses. 2015 Jun;84(6):570-6. doi: 10.1016/j.mehy.2015.03.006. Epub 2015 Mar 6.

PMID:
25801344
41.

Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension.

Thakkar V, Nikpour M, Stevens WM, Proudman SM.

Intern Med J. 2015 Mar;45(3):248-54. doi: 10.1111/imj.12691. Review.

PMID:
25735576
42.

Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group.

Khanna D, Mittoo S, Aggarwal R, Proudman SM, Dalbeth N, Matteson EL, Brown K, Flaherty K, Wells AU, Seibold JR, Strand V.

J Rheumatol. 2015 Nov;42(11):2168-71. doi: 10.3899/jrheum.141182. Epub 2015 Mar 1. Review.

43.

The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies--a systematic review.

Mohamed HJ, Sorich MJ, Kowalski SM, McKinnon R, Proudman SM, Cleland L, Wiese MD.

Eur J Clin Pharmacol. 2015 Apr;71(4):411-23. doi: 10.1007/s00228-015-1819-x. Epub 2015 Feb 18. Review.

PMID:
25687918
44.

A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis.

Hao Y, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C, Youssef P, Gabbay E, Roddy J, Walker J, Zochling J, Sahhar J, Nash P, Lester S, Rischmueller M, Proudman SM, Nikpour M.

Arthritis Res Ther. 2015 Jan 18;17:7. doi: 10.1186/s13075-015-0517-5.

45.

A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine.

Wojciechowski J, Wiese MD, Proudman SM, Foster DJ, Upton RN.

Br J Clin Pharmacol. 2015 May;79(5):777-88. doi: 10.1111/bcp.12553.

46.

The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity.

Hopkins AM, O'Doherty CE, Foster DJ, Suppiah V, Upton RN, Spargo LD, Cleland LG, Proudman SM, Wiese MD.

J Clin Pharm Ther. 2014 Oct;39(5):555-60. doi: 10.1111/jcpt.12189. Epub 2014 Jul 8.

PMID:
25040563
47.

Does periodontal treatment influence clinical and biochemical measures for rheumatoid arthritis? A systematic review and meta-analysis.

Kaur S, Bright R, Proudman SM, Bartold PM.

Semin Arthritis Rheum. 2014 Oct;44(2):113-22. doi: 10.1016/j.semarthrit.2014.04.009. Epub 2014 Apr 28. Review.

PMID:
24880982
48.

Individualization of leflunomide dosing in rheumatoid arthritis patients.

Hopkins AM, O'Doherty CE, Foster DJ, Upton RN, Proudman SM, Wiese MD.

Per Med. 2014 Jun;11(4):449-461. doi: 10.2217/pme.14.23.

PMID:
29783485
49.

RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.

Cleland LG, Proudman SM, James MJ.

J Natl Cancer Inst. 2014 Apr;106(4):dju022. doi: 10.1093/jnci/dju022. Epub 2014 Mar 31. No abstract available.

PMID:
24685932
50.

Changes in peripheral blood B cell subsets at diagnosis and after treatment with disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: correlation with clinical and laboratory parameters.

McComish J, Mundy J, Sullivan T, Proudman SM, Hissaria P.

Int J Rheum Dis. 2015 May;18(4):421-32. doi: 10.1111/1756-185X.12325. Epub 2014 Mar 2.

PMID:
24589014

Supplemental Content

Loading ...
Support Center